Orlistat pubmed

Orlistat-Associated Adverse Effects and Drug Interactions PDF. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Official Full-Text Publication Orlistat-Associated Adverse Effects and Drug Interactions on. DOI 10.2165/00002018-200831010-00005 Source PubMed.

Clinical efficacy of orlistat therapy in overweht and obese patients. Randomized controlled trials (RCTs) were excluded for the following reasons: nonapproved drug or drug combination, participants were children, not published in English, no placebo , did not meet criteria for size, duration, or attrition, not an intention-to-treat analysis, or insufficient description of data analysis. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research . Pub Med Article Wing RR, Lang W, Wadden TA, et al; Look AHEAD Research . Pub Med Article Wadden TA, Volger S, Tsai AG, et al; POWER-UP Research . Pub Med Article US Dept of Health and Human Services. Clinical efficacy of orlistat therapy in overweht and obese patients with insulin-treated type 2 diabetes A. PMID 12032111; PubMed - indexed for MEDLINE.

Orlistat for obesity benefits beyond weht loss. - NCBI ) is used as an adjunct to caloric restriction, increased physical activity, and behavioral modification in the treatment of exogenous obesity; also used to reduce the risk of weht regain after initial loss. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Orlistat lowers lipids and improves insulin sensitivity, but its effect on other metabolic syndrome related. PMID 15620437; PubMed - indexed for MEDLINE.

Orlistat a review of its use in the management of obesity. - NCBI JAMAJAMA Cardiology JAMA Dermatology JAMA Facial Plastic Surgery JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) A Pub Med search was conducted from inception to September 15, 2013, to find long-term (≥1-y) placebo-controlled randomized clinical trials and meta-analyses investating drugs currently US Food and Drug Administration–approved alone or in combination for an obesity or weht-management indication. Orlistat a review of its use in the management of obesity. Orlistat is generally well tolerated. Thus. PMID 16956313; PubMed - indexed for MEDLINE.

Effect of orlistat on cardiovascular disease risk in obese adults. - NCBI Alli diet pills are available over-the-counter as a weht-loss aid. AIM The aim of this study is to compare the effect of orlistat vs. placebo on the predicted 10-year. PMID 15811142; PubMed - indexed for MEDLINE.


Orlistat pubmed:

Rating: 88 / 100

Overall: 95 Rates